Altimmune Q1 net loss $19.4M ($0.44/share); cash $180.0M; key pemvidutide data readouts Q3/Q4 2022

Altimmune, Inc.

2022-Q1 EPS reported -$0.44 revenue$32,000

Net loss of $19.4M ($0.44 per share) vs $14.9M ($0.38) in Q1 2021; R&D expense $15.1M.
Cash, cash equivalents and restricted cash totaled $180.0M at March 31, 2022.
Pemvidutide Phase 2 MOMENTUM obesity trial enrolling ~320 subjects; interim 24-week data expected Q4 2022.
Phase 1b NAFLD trial enrollment completed; 12-week liver fat and weight loss data expected Q3 2022.
HepTcell Phase 2 chronic hepatitis B trial continuing; data readout expected H1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.